Business Context and Reporting Period
This Form 8-K was filed by Aclaris Therapeutics, Inc. on July 23, 2021. The report details the termination of a material definitive agreement involving the full repayment of a loan facility.
Key Financial Metrics
The filing discloses specific cash outflows related to debt repayment but does not provide broader financial metrics such as revenue, profit, or operating cash flow.
- Principal Repaid: $11.0 million
- Accrued Interest Paid: Approximately $45,000
- Final Payment Fee: $550,000
- Prepayment Fee: $120,000
- Total Cash Outflow: Approximately $11.715 million
Material Changes
On July 23, 2021, the Company repaid in full the $11.0 million borrowed under the Loan and Security Agreement dated March 30, 2020, with Silicon Valley Bank. Following this transaction, all obligations under the agreement were terminated, except for those explicitly set forth in the agreement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the debt termination. The unusual item reported is the specific fee structure associated with the early termination of the loan.
Investor Verification Checklist
- Verify the impact of the $11.715 million cash outflow on the Company's current liquidity position.
- Confirm the status of any remaining obligations under the terminated Loan and Security Agreement.
- Review subsequent filings for updates on the Company's cash runway following this significant debt repayment.